Trials / Completed
CompletedNCT04760704
Covid-19 Vaccine Response in Elderly Subjects
Evaluation of the Immunogenicity of mRNA BNT162b2 (COMIRNATY®) Vaccine in Elderly Subjects by Monitoring the Specific Cellular and Humoral Response.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 264 (actual)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Accepted
Summary
The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9 months, in subjects residing in medical establishment for dependent elderly persons, compared to immunocompetent subjects aged 40 to 65 years (control subjects for vaccination over the same period).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration | Specific T cells and specific antibodies assessment |
Timeline
- Start date
- 2021-02-18
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
- First posted
- 2021-02-18
- Last updated
- 2025-12-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04760704. Inclusion in this directory is not an endorsement.